Market revenue in 2023 | USD 73.2 million |
Market revenue in 2030 | USD 100.6 million |
Growth rate | 4.6% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III |
Key market players worldwide | Almac Group, Catalent Inc, Waldencast PLC Class A, PCI Technology, Sharp Corp, Thermo Fisher Scientific Inc, PAREXEL, Marken, KLIFO, BioCair |
Phase iii was the largest segment with a revenue share of 52.32% in 2023. Horizon Databook has segmented the Canada clinical trial supplies market based on phase i, phase ii, phase iii covering the revenue growth of each sub-segment from 2018 to 2030.
Canada accounts for 4.0% of the total number of clinical trials and stands fourth in terms of clinical trial sites. Presence of an advanced health & education system, government support, and presence of a diverse population are among the main factors driving the growth of clinical trial supplies market.
Major biopharmaceutical companies conduct clinical trials in Canada, which makes the country a lucrative market for players operating in clinical trial supplies market. These factors are expected to drive growth of clinical trial supplies market in the country.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account